Orthocell Posts 11% Quarterly Revenue Growth to $3 Million
Orthocell Limited has reported a record $3 million quarterly revenue, driven by strong sales of its nerve repair product Remplir in Australia and Singapore, while advancing its rollout in the US and Canada ahead of schedule.
- Record $3 million revenue for September quarter, up 11% sequentially
- Six consecutive quarters of revenue growth with 11% compound quarterly growth rate
- US Remplir rollout ahead of schedule with initial sales and expanding distributor network
- First Canadian distributor appointed, targeting early sales in December quarter
- Leadership team strengthened with new CFO, CCO, and Non-Executive Director appointments
Record Revenue Momentum
Orthocell Limited (ASX, OCC), a regenerative medicine company specialising in nerve repair, has delivered a standout performance in the September 2025 quarter with record revenue of $3 million. This marks an 11% increase over the previous quarter’s record of $2.7 million and continues a remarkable streak of six consecutive quarters of growth, underscoring strong market adoption of its flagship product, Remplir.
The company’s revenue growth is primarily driven by expanding sales in Australia and Singapore, where Remplir has gained significant traction among surgeons. Orthocell’s ability to sustain an 11% compound quarterly growth rate since Q2 FY24 highlights the product’s growing acceptance and the company’s effective commercial strategy.
Accelerated US and Canadian Market Entry
Orthocell’s US commercialisation of Remplir is progressing ahead of schedule, with initial surgeries completed across multiple hospitals and over 100 surgeons introduced to the product. The company has secured a nerve repair specialist distributor network covering 25 states and approximately 40% of the US population. Early revenue contributions from the US market have already begun, with expectations for significant growth in the December quarter and into the second half of FY26.
In parallel, Orthocell has made a strategic entry into the Canadian market by appointing its first distributor for Alberta and British Columbia, with further provincial appointments anticipated. The Canadian rollout targets first sales in the December 2025 quarter, leveraging synergies with the US commercial team already in place.
Clinical Advances and Market Potential
Beyond commercial expansion, Orthocell is exploring new clinical applications for Remplir, notably in nerve-sparing prostate cancer surgery, a globally significant opportunity given prostate cancer’s prevalence. Early patient data from 40 surgical cases in Australia is expected in Q4 CY25, with preliminary study results showing an impressive 81% success rate and no reported complications. This promising indication could substantially enlarge Orthocell’s total addressable market.
Strengthened Leadership and Financial Position
Orthocell has bolstered its executive team with the appointments of Jim Piper as Chief Financial Officer and Adam Wood as Chief Commercial Officer, alongside Michael McNulty joining the board as a Non-Executive Director. These additions bring seasoned expertise to support the company’s ambitious growth plans.
Financially, Orthocell remains well-capitalised with $27 million in cash reserves at quarter-end, providing a solid foundation for ongoing commercial expansion, regulatory approvals, and research and development activities.
Bottom Line?
Orthocell’s robust growth and strategic market expansions set the stage for a pivotal year ahead as US and Canadian sales ramp up and new clinical data emerges.
Questions in the middle?
- How quickly will US Remplir sales scale beyond initial early-stage revenue?
- What impact will the forthcoming prostate cancer surgery data have on market adoption?
- Can Orthocell secure further distributor appointments across Canada and other key markets?